Skip Navigation

Canine Oncology

Canine Study 1:

Title: Activated autologous T cell killing of CD 20+ B cell lymphoma in the Dog.
Contact Person: Heather Wilson, DVM, DACVIM (Oncology)
Clinic Phone: 979-845-2351
Email: animalcancer@cvm.tamu.edu
Species: Canines
Inclusion Criteria and General Background Information: Any dog weighing over 35 lbs that has been diagnosed with B cell Lymphoma and is being treated with prednisone alone.
Exclusion Criteria: Dogs with significant concurrent disease are excluded from this study. Dogs receiving other therapies including chemotherapy or radiation therapy (other than prednisone) are not eligible for this study. Dogs with T cell lymphoma are not eligible for this study.
Owner Commitments: Dogs will have an initial blood draw to isolate T cells from the blood. 6 weeks later, three infusion will begin. These will be given every other week for a total of 6 weeks. A blood sample collection will be necessary for the off weeks. 7-10 days after completion of therapy a biopsy of one lymph node and blood work will be collected. Animals will be sedated or anesthetized for the sample collection. Blood sample collections and physical exams will occur monthly thereafter.
Financial Incentives:

Immunophenotyping (determination of the type of lymphoma using special stains) will be done free of charge for all dogs with Lymphoma entering the study. The manufacturing of the T cell infusion and visit costs associated with these infusions will be paid for by the study.
 

This study is currently open.

Canine Study 2:

Title: Alteration of the intestinal microflora after chemotherapy in dogs.
Contact Person: Heather Wilson, DVM, DACVIM (Oncology)
Clinic Phone: 979-845-2351
Email: animalcancer@cvm.tamu.edu
Species: Canines
Inclusion Criteria and General Background Information: Your dog must have a confirmed diagnosis of cancer and receive doxorubicin (a chemotherapy drug) as part of their treatment protocol. Two pretreatment fecal (stool) samples are needed and may be frozen before your first appointment.
Exclusion Criteria: Dogs with significant concurrent disease are excluded from this study. Dogs receiving probiotics of any type (e.g. Fortiflora ®) will be excluded. Dogs with significant pre-existing intestinal disease will also be excluded.
Owner Commitments: You will be required to collect and bring in (or send in by mail) two pretreatment fecal samples as well as collect fecal sample the week before and 72 hours after doxorubicin chemotherapy. Blood will also be drawn at the first visit and possibly at subsequent visits for evaluation of B vitamin levels.
Financial Incentives:

All costs associated with this study will be provided as part of your participation. After entering the study fecal collection tubes will be provided and shipping for any samples will be paid. Costs associated with diagnosis, staging and doxorubicin therapy will be the responsibility of the owner.

This study is currently open. We have also partnered with Capital Area Veterinary Specialists (Dr. Meighan Daly) in Austin for this project! Please click here to visit their website for appt details http://cavstvo.com/.

Canine Study 3:

Title: S100b inhibitors for the treatment of canine malignant melanoma
Contact Person: Heather Wilson, DVM, DACVIM (Oncology)
Clinic Phone: 979-845-2351
Email: animalcancer@cvm.tamu.edu
Species: Canines
Inclusion Criteria and General Background Information: Your dog must have a confirmed diagnosis of melanoma and several tests to ensure his/her general health and to assess how advanced the disease is prior to treatment. The tumor will be biopsied prior to therapy. Tumors must be large enough to biopsy and your dog must have no other significant health problems.
Exclusion Criteria: Dogs with significant concurrent disease are excluded from this study. Dogs cannot be receiving concurrent chemotherapy (including corticosteroids) or radiation therapy. Dogs must be off of all such therapy for 3 weeks prior to study enrollment. No dogs under 15 kg (<33 lbs) will be allowed in this study.
Owner Commitments: Prior to entry into this study, your dog must have a confirmed diagnosis of melanoma and staging tests to ensure his/her general health and to assess how advanced the disease is. The tumor will need to be biopsied before therapy for this purpose. Your dog will receive one of two drugs or a combination of the two. Both drugs are FDA approved and have been used in dogs previously for other reasons. Interactions between these drugs and other drugs are unknown; therefore it is important to tell your veterinarian about any medications (and supplements) your dog is currently taking. It is strongly encouraged to eliminate all unnecessary medications. This should be discussed with your oncologist if you have any questions.
Financial Incentives:

All costs associated with this study will be provided as part of your participation. In the event any complications arise during the twenty-nine (29) day study period (time period between drug administration and assessment), their management will be covered by study funds up to $1000/dog. This would include any unanticipated hospitalizations. However, all costs exceeding $1000/dog are your responsibilty.

This trial is currently open!

Canine Study 4:

Title: Metronomic chemotherapy with and without palladia for canine with appendicular osteosarcoma
Contact Person: Heather Wilson, DVM, DACVIM (Oncology)
Clinic Phone: 979-845-2351
Email: animalcancer@cvm.tamu.edu
Species: Canines
Inclusion Criteria and General Background Information: Any dog weighing over 35 lbs that has been diagnosed with Osteosarcoma (OSA) of the limb and is generally otherwise healthy. Dogs must have a histologic diagnosis of OSA and start the study within 14 days of amputation of the affected limb.
Exclusion Criteria: Dogs with significant concurrent disease are excluded from this study. Dogs receiving other therapies including chemotherapy or radiation therapy are not eligible for this study. Dogs must be off all non-steriodal anti-inflammatory drugs for at least 48 hours before enrolling. Dogs with metastasis are not eligible for this study.
Owner Commitments: Dogs will receive 4 doses of Carboplatin as part of standard of care therapy for OSA once every 3 weeks. After the completion of chemotherapy dogs will be randomized into one of two groups: dogs receiving cyclophosphamide and piroxicam or cyclophosphamide, piroxicam and palladia metronomic chemotherapy to be delivered orally by the owner at home with recheck blood work and chest radiographs every other month for 1 year.
Financial Incentives:

The costs of the drugs associated with this study and some of the office visit costs are covered by this study. This study is part of a collaboration with The Ohio State University.

This study is currently open!

Canine Study 5:

Title: Radiation Therapy for dogs with multicentric lymphoma
Contact Person: Michael Deveau, MS, DVM, DAVR(Radiation Oncology)
Clinic Phone: 979-845-2351
Email: animalcancer@cvm.tamu.edu
Species: Canines
Inclusion Criteria and General Background Information: Any dog weighing over 10 lbs that has been newly diagnosed with lymphoma.
Exclusion Criteria: Dogs with significant concurrent disease are excluded from this study. Dogs receiving other therapies including chemotherapy or radiation therapy (other than prednisone) are not eligible for this study.
Owner Commitments: Dogs will receive full body imaging before therapy, then treated with chemotherapy for 19 weeks (stnadard therapy for canine lymphoma), after completion of chemotherapy dogs will receive 2 weeks (10 doses, M-F) of radiation therapy.
Financial Incentives:

The costs of the imaging associated with the study as well as some of the staging costs, radiation therapy costs, anesthesia costs and some blood work costs will be covered by this study. The cost of chemotherapy will be the responsibility of the owner.

This study is currently open!

Canine Study 6:

Title: Evaluation of Iniparib in tumor-bearing dogs
Contact Person:

Heather Wilson, DVM, DACVIM (Oncology) Clinic Phone: 979-845-2351
Email: animalcancer@cvm.tamu.edu
Species: Canines
Inclusion Criteria and General Background Information: Any dog weighing over 21 lbs that has been diagnosed with melanoma, squamous cell carcinoma, soft tissue sarcoma or mammary carcinoma.
Exclusion Criteria: Dogs with significant concurrent disease are excluded from this study. Dogs may not have received chemotherapy within 2 weeks or radiation therapy within 6 weeks of enrolling.
Owner Commitments: Each dog will participate for 15-22 days in the study. There are two groups of dogs that will be enrolled. Group A will be dogs with any of the above tumor types and Group B is for dogs with mammary carcinoma only.
Financial Incentives:

The basic staging for enrollment (chest radiographs, blood work, tumor diagnosis and urinalysis) are the responsibility of the owner. All other costs of the study are covered by the study. In addition, a gift of $1000 towards additional cancer therapy is available for all patients who complete the study. There is also a fund available to cover any side effects of the study up to $2000.

This trial is currently open!

 

Canine Study 7:

Title:

Evaluation of new renal (kidney) biomarkers for kidney damage in normal dogs and dogs receiving nephrotoxic drugs.
Contact Person:

Heather Wilson, DVM, DACVIM (Oncology) Clinic Phone: 979-845-2351
Email: animalcancer@cvm.tamu.edu
Species: Canines
Inclusion Criteria and General Background Information:

Dogs receiving kidney toxic drugs (e.g., tyrosine kinase inhibitors):

  • Must be at least 2 years old
  • Must weigh at least 22 lbs
  • Must have no previous history of kidney disease or protein in the urine
  • Must have a life expectancy of at least 4 months
Exclusion Criteria: Dogs with significant concurrent disease are excluded from this study. Dogs with kidney disease, current urinary tract infections or protein in the urine are also excluded from this study.
Owner Commitments:

Dogs receiving Kidney toxic drugs (e.g., tyrosine kinase inhibitors) will participate for up to 6 months with a pretreatment blood and urine sample, and additional samples two weeks after initiation of therapy and then monthly thereafter.
Financial Incentives:

All laboratory tests associated with kidney panel will be covered by the study. Any additional costs or therapies will be the responsibility of the owner.

This trial is currently open!

Canine Study 8:

Title: Compassionate use of KPT-335 in dogs with spontaneous tumors.
Contact Person:

Heather Wilson, DVM, DACVIM (Oncology) Clinic Phone: 979-845-2351
Email: animalcancer@cvm.tamu.edu
Species: Canines
Inclusion Criteria and General Background Information: Any dog weighing over 10 lbs that has been diagnosed with melanoma, mast cell tumor, osteosarcoma or lymphoma who has failed standard therapy, for whom standard therapy is not availalbe or for those cases in which standard therapy has been declined by the owner.
Exclusion Criteria: Dogs with significant concurrent disease are excluded from this study. Dogs weighing less than 10 lbs are excluded from the study.
Owner Commitments: Each dog will participate for 28 days in the study. Dogs will be started on oral KPT-335 on a Mon, Wed, Fri schedule for 28 days.  The dose will be escalated a little each week as long as it is being well tolerated.
Financial Incentives:

The basic staging for enrollment (chest radiographs, blood work, tumor diagnosis and urinalysis) are the responsibility of the owner. All other costs of the study are covered by the study. In addition, a fund is available to cover any side effects of the study up to $750.

This trial is opening soon. Please check back!

Additionally we are always looking for dogs with osteosarcoma and mammary carcinoma who are willing to donate blood samples and/or tissue after surgical removal for several investigational studies that may help support future clinical trials in humans and dogs!